SCOLR Pharma, Inc. Reports First Quarter 2007 Financial Results.

BELLEVUE, Wash. -- SCOLR Pharma, Inc. (AMEX: DDD) today reported financial results for the three months ended March 31, 2007. The Company will host a live conference call today, May 8, 2007, at 11:30 a.m. (Eastern Daylight Time).

Total revenues increased significantly to $1.1 million for the three months ended March 31, 2007, compared to $92,846 for the same period in 2006. The increase was primarily a result of the recognition of approximately $609,000 of research and development income and an additional $173,000 of licensing fee income attributable to the Company's terminated agreement with Wyeth Consumer Healthcare (Wyeth). Revenues were also increased by royalty income of over $252,000 from SCOLR's alliance with Perrigo, which has introduced four Controlled Delivery Technology (CDT[R]) based nutritional products, including three in late 2006. SCOLR anticipates this will result in a higher level of royalty revenues during 2007.

Net loss decreased 39%, or $1.2 million to $1.9 million for the three months ended March 31, 2007, primarily due to increased revenues, as compared to $3.1 million for the same period in 2006.

First Quarter 2007 Highlights include:

* Preparations continued for submission of SCOLR's first Abbreviated New Drug Application for a 12 hour CDT-based pseudoephedrine later this year.

* Promising bioavailability testing results were reported from SCOLR's once-daily 24 mg CDT-ondansetron tablets, compared to three immediate release 8 mg Zofran[R] reference tablets dosed at 0, 8, and 16 hours;

* Preclinical evaluation of initial oral Peramivir formulations are now planned for late 2007. Peramivir is currently being tested by BioCryst as a potential intramuscular and intravenous treatment for seasonal and life-threatening influenza;

* Initial formulation development was completed of an undisclosed CDT-based application for a major consumer products company; prototype preparations for commercial viability testing is planned for late 2007;

* Development started of once-daily CDT-based risperidone and rivastigmine formulations, with the goal to start testing in late 2007/early 2008. Risperidone is for the management of schizophrenia and bipolar mania and had 2006 reported global sales of approximately $3.3 billion. Rivastigmine is for the management of Alzheimer's Disease and in 2006 reported global sales of approximately $525 million;

* As previously reported, Wyeth terminated the Development and Licensing Agreement to use SCOLR's CDT oral drug delivery technology in products containing ibuprofen. The agreement was terminated without cause effective April 16, 2007. The research and development income recognized during the three months ended March 31, 2007, included a $500,000 milestone payment from Wyeth, approximately $109,000 reimbursement of research and development costs, and previously deferred licensing fee income.

Daniel O. Wilds, SCOLR Pharma's President and CEO, stated that, "We made solid progress in the first quarter. We added to and advanced our product development pipeline consistent with our specialty pharmaceutical business strategy.

"Although initially disappointed by Wyeth's decision to terminate our CDT-ibuprofen agreement, we are encouraged by the number of potential licensing and partnership inquiries from other pharmaceutical companies now interested in our CDT-based extended-release ibuprofen program. We are optimistic that we will be able to identify a new partner to advance our ibuprofen program but we are prepared to develop ibuprofen products ourselves as well."

Mr. Wilds added, "On a more personal note, we are saddened by the untimely passing of Dr. Michael Sorell, a valued board member and respected colleague, on April 20, 2007. Dr. Sorell joined our board in April 2004. He was an important contributor to our product development selection process. We extend our deepest condolences to his family and friends and will be among those who will miss his valuable counsel, business and medical acumen, and his special friendship."

SCOLR's strategy includes a significant continued commitment to research and development activities to grow its drug delivery program. Research and development expenses increased 35% or $462,581, to approximately $1.8 million for the three months ended March 31, 2007, compared to approximately $1.3 million for the same period in 2006. This increase is primarily due to an increase of $252,063 for supplies and clinical trial expenses related to our projects and an increase of $140,352 in salaries and related benefit expenses and additional R&D staff. We expect research and development costs to increase during 2007 as we continue to advance our development efforts.

General and administrative expenses decreased 34%, or $610,811, to $1.2 for the three months ended March 31, 2007, compared to $1.8 for the same period in 2006, primarily due to reduced expenses associated with compliance with the Sarbanes-Oxley Act of 2002, and Financial Accounting Standard 123R implementation costs in 2006.

As of March 31, 2007, the Company had $14.7 million of working capital compared to $16.2 million as of December 31, 2006. The Company believes that its cash, cash equivalents and short-term investments will be sufficient to fund its operations at planned levels through early 2008.

Product Information

Ondansetron hydrochloride is the active ingredient in Zofran[R], GlaxoSmithKline's tablet and injection formulations to prevent chemotherapy and radiation related nausea and vomiting. Peramivir is the active ingredient in BioCryst's intramuscular and intravenous treatment being evaluated in clinical trials for seasonal and life threatening influenza. Risperidone is the active ingredient in Risperdal[R], Janssen, L.P.'s product for the management of schizophrenia and bipolar mania. Rivastigmine is the active ingredient in Excelon[R], Novartis' product for the management of Alzheimer's disease. Fenofibrate is the active ingredient in Tricor[R], an Abbott product for hypercholesterolemia (elevated total cholesterol).

Conference Call

As previously announced, SCOLR Pharma will host a conference call on May 8, 2007, at 11:30 a.m. (Eastern Daylight Time). Shareholders and other interested parties may participate in the conference call by dialing [phone] (domestic) or [phone] (international) and entering access code 89259681, a few minutes before 11:30 a.m. EDT on May 8, 2007. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.scolr.com.

A replay of the conference call will be accessible two hours after its completion through May 22, 2007, by dialing [phone] (domestic) or [phone] (international) and entering access code 30759942. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com, www.streetevents.com and www.scolr.com.

About SCOLR Pharma:

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company. SCOLR Pharma's corporate objective is to combine its formulation expertise and its patented CDT platform to develop novel pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425.373.0171 or visit http://www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to successfully develop new formulations and complete research and development, including pre-clinical and clinical studies, our ability to raise additional funds, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions. For example, if our clinical trials are not successful or take longer to complete than we expect, we may not be able to develop and commercialize our products. And we may not obtain regulatory approval for our products, which would materially impair our ability to generate revenue. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

[TABLE OMITTED]
[TABLE OMITTED]